dilated cardiomyopathy
Conditions
Interventions
Benidipine, twice a day, 2mg to 8mg per day, for 6 months
no intervention
Sponsors
Tohoku University Graduate School of Medicine
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Patients who are diagnosed as dilated cardiomyopathy definitely or suspiciously and meet following criteria; 1) Ejection Fraction <=40% and >=20%, 2) without valvular disease and significant stenosis or obstruction in coronary arteries, and who are excluded secondary cardiomyopathy by myocardial biopsy, 3) who are in stable status with symptoms of NYHA 1 to 3 within 3 months before intervention
Exclusion criteria
Exclusion criteria: 1) Patients who have ischemic heart disease, valvular disease, acute myocarditis, and secondary cardiomyopathy 2) Patients who have been taking calcium channel blocker 3) Patients in unstable status with symptoms of NYHA 4 4) Patients having serious liver dysfunction or having serious renal dysfunction requiring hemodialysis 5) Patients who are intolerant to dihydropyridine calcium channel blocker 6) Patients with a contraindication to dihydropyridine calcium channel blocker 7) Patients who are pregnant 8) Patients who did not consent to the trial 9) Patients who were considered as inappropriate candidates for the trial by phsicians
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Ejection Fraction at 6 months after the initiation of the treatment | — |
Countries
Japan
Contacts
Public ContactKatsuya Kozu
Tohoku University Graduate School of Medicine Cardiovascular Medicine
Outcome results
None listed